查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008677

擴大性心肌病治療市場：依治療分類、治療方法、給藥途徑、最終用戶和分銷管道分類－2026-2032年全球市場預測

Dilated Cardiomyopathy Therapeutics Market by Therapeutic Class, Treatment Modality, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，擴大性心肌病治療市場價值將達到 4.9366 億美元，到 2026 年將成長至 5.3772 億美元，到 2032 年將達到 7.9062 億美元，複合年成長率為 6.95%。

主要市場統計數據
基準年 2025 4.9366億美元
預計年份：2026年 5.3772億美元
預測年份 2032 7.9062億美元
複合年成長率 (%) 6.95%

這是一本權威的入門書籍，概述了現代擴大性心肌病治療的臨床複雜性、不斷發展的多學科護理和動態創新。

擴大性心肌病（DCM）是一種複雜的臨床症候群，其特徵是心室擴張和收縮功能障礙，導致不同患者群體出現顯著的發病率和死亡率。過去十年，治療策略已從傳統的神經激素阻斷療法擴展到包括先進的器械介入和針對遺傳及分子因素的精準醫療。這種發展要求相關人員重新評估診療路徑、資源分配和長期管理模式，以反映漸進式改善和突破性創新。

醫療器材技術創新、精準生物製藥以及醫療保健服務體系的重新設計如何從根本上重塑擴張型心肌病變的治療路徑和相關人員的獎勵。

擴大性心肌病的治療格局正經歷一場變革，其驅動力包括技術進步、監管環境的演變以及醫療服務模式的轉變。曾經僅用於緊急救生措施的醫療設備，如今正被納入臨床診療路徑的早期階段，因為越來越多的證據表明它們對降低發病率和提高生存率具有積極作用。同時，醫療器材的小型化和遠端監測技術的進步也正在改變門診就診和追蹤的頻率。

評估 2025 年價格調整將如何重塑全球醫療設備、生物製藥和基因治療材料在心肌病。

將於2025年實施的新關稅措施將進一步加劇擴大性心肌病治療藥物的全球供應鏈和成本結構的複雜性，尤其是在跨境生物製藥零件和原料方面。心臟再同步治療系統、植入式心臟整流去顫器和心室輔助裝置等醫療設備依賴複雜的全球製造網路，該網路供應半導體、感測器和特種合金等零件。上游供應商面臨的關稅壓力可能會蔓延至醫療器材製造商，可能會給醫院和採購商帶來價格壓力。

將治療分類、治療方法、給藥途徑、醫療保健機構和分銷管道與臨床和商業策略聯繫起來的綜合細分洞察。

擴大性心肌病觀點分析擴張型心肌病變治療，透過考慮治療分類、治療方法、給藥途徑、終端用戶環境和通路，可以揭示不同的機會和應用趨勢。將治療分類細分為ACE抑制劑、ARB、ARNI、 BETA阻斷劑、器械療法、利尿劑和基因療法，可以發現，儘管藥物治療仍然至關重要，但器械療法和基因療法具有獨特的臨床和商業性特徵。此外，將器械療法細分為CRT、ICD和VAD，突顯了投資和治療路徑的多樣化需求。觀點治療方法（器械療法、基因療法、藥物療法），並認知到藥物研發正在向生物製劑和小分子藥物方向發展，可以明確區分哪些領域研發風險和監管複雜性較高，哪些領域更易於進行漸進式臨床最佳化。

區域趨勢分析解釋了美洲、歐洲、中東和非洲以及亞太地區的監管、報銷和基礎設施因素如何影響治療方法。

區域趨勢正在以不同的方式影響擴大性心肌病)治療的研發、引進和應用，美洲、歐洲、中東和非洲 (EMEA) 以及亞太地區的情況。在美洲，成熟的醫療基礎設施和完善的報銷機制支持先進醫療設備和新一代生物製劑的快速引進，但支付者越來越要求提供嚴謹的衛生經濟學證據來證明高昂治療費用的合理性。臨床網路和高度專業化的中心有助於患者參與複雜的手術和臨床試驗，而私人和公共保險公司正在就影響商業化策略的福利條件進行談判。

企業定位與競爭策略：揭示醫療設備領導企業、生技藥品開發商和基因治療先驅如何整合自身能力以確保長期競爭優勢。

擴大性心肌病治療市場格局呈現出多元化大型醫療設備製造商、專業生技藥品研發公司和新興基因治療創新者策略融合的趨勢。成熟的循環系統醫療設備公司持續投資於下一代植入式系統、遠端監測生態系統以及治療前後的服務模式，以改善患者的長期療效並創造持續的業務收益。這些成熟公司積極尋求補充性收購、合作開發夥伴關係和廣泛的臨床項目，以拓展業務至相關附加價值服務領域，同時保持其在醫療設備領域的領先地位。

領導者必須應對的策略挑戰，以增強證據產生、供應韌性和跨治療方法和醫療保健環境的全面商業化。

產業領導企業應採取多管齊下的策略，優先考慮證據生成、供應鏈韌性和整合商業化，以在擴大性心肌病治療領域獲得臨床和商業性價值。首先，透過可操作的臨床試驗、真實世界數據 (RWE) 計畫和註冊登記來加強證據基礎至關重要，這有助於說服臨床醫生和保險公司相信治療的額外益處，尤其是在高成本醫療設備和基因療法領域。建立可互通的數據平台，以促進長期療效追蹤，將有助於開展基於價值的對話和上市後舉措。

透明的調查方法，結合文獻綜述、相關人員訪談、臨床註冊分析和情境評估，得出了可靠的策略結論。

本次高階主管分析的基礎研究結合了對同儕審查文獻、監管申報文件和臨床試驗註冊庫的系統性回顧，以及針對整個生態系統的重點一手研究。文獻整合涵蓋了最新的指南、共識聲明和具有重大影響的臨床研究，以確保與目前的醫療標準保持一致。研究人員仔細審查了臨床試驗註冊庫和已發布的監管申報文件，以整理醫療設備和基因治療候選藥物的臨床實驗項目和預期里程碑。

一項權威的綜合分析重點闡述了臨床創新、證據深度和操作適用性將如何決定未來擴大性心肌病。

擴大性心肌病的治療方法正處於轉折點，器械創新、生物製藥的進步以及基因組醫學的融合，在拓展治療可能性的同時，也增加了研發、交付和報銷流程的複雜性。能夠將臨床嚴謹性與營運靈活性相結合的相關人員，將更有能力將科學進步轉化為對患者有意義的治療效果和永續的商業模式。在瞬息萬變的醫療保健格局中，有必要重新評估投資重點，並專注於實證醫學的產生、區域價值鏈策略以及以價值為導向的商業化。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：擴大性心肌病治療藥物市場（依治療分類）

  • ACE抑制劑
  • ARB
  • ARNI
  • BETA阻斷劑
  • 器械療法
    • CRT
    • ICD
    • VAD
  • 利尿劑
  • 基因治療

第9章：擴大性心肌病治療市場（依治療方法分類）

  • 器械療法
  • 基因治療
  • 藥物治療
    • 生物製藥
    • 低分子化合物

第10章：擴大性心肌病治療市場：依給藥途徑分類

  • 靜脈
  • 口服

第11章：擴大性心肌病治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第12章：擴大性心肌病治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：擴大性心肌病治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：擴大性心肌病治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：擴大性心肌病治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國擴大性心肌病治療藥物市場

第17章：中國擴大性心肌病治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc
  • CH Boehringer Sohn AG & Co. KG
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline（GSK）
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co, Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol-Myers Squibb Company
  • The Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals
  • Viatris Inc.
Product Code: MRR-8E22B61932B4

The Dilated Cardiomyopathy Therapeutics Market was valued at USD 493.66 million in 2025 and is projected to grow to USD 537.72 million in 2026, with a CAGR of 6.95%, reaching USD 790.62 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 493.66 million
Estimated Year [2026] USD 537.72 million
Forecast Year [2032] USD 790.62 million
CAGR (%) 6.95%

An authoritative introduction framing the clinical complexity, multidisciplinary care evolution, and innovation dynamics shaping modern dilated cardiomyopathy therapeutics

Dilated cardiomyopathy (DCM) represents a complex clinical syndrome characterized by ventricular dilation and systolic dysfunction that leads to substantial morbidity and mortality across diverse patient populations. Over the past decade, therapeutic strategies have expanded beyond traditional neurohormonal blockade to include advanced device interventions and precision medicines that target genetic and molecular drivers. This evolution compels stakeholders to reassess care pathways, resource allocation, and long-term management models to reflect both incremental improvements and step-change innovations.

Clinical practice is adapting to a more heterogeneous patient profile, where early identification of genetic etiologies and nuanced phenotyping inform personalized treatment plans. As a result, multidisciplinary teams spanning cardiology, electrophysiology, genetics, and allied health professionals are increasingly central to therapy selection and ongoing monitoring. Payers and health systems are likewise recalibrating coverage frameworks to address up-front costs associated with devices and gene-based interventions while evaluating downstream reductions in hospitalizations and complications.

From an innovation perspective, the interplay between device engineering, biologic therapeutics, and small-molecule optimization has created a richer set of options for clinicians and patients. Consequently, strategic planning in this therapeutic area requires a granular understanding of segment dynamics, regulatory trajectories, clinical trial readouts, and real-world evidence as they converge to influence adoption, care delivery, and investment priorities.

How converging device innovation, precision biologics, and care delivery redesign are fundamentally reshaping therapeutic pathways and stakeholder incentives in dilated cardiomyopathy

The therapeutic landscape for dilated cardiomyopathy is undergoing transformative shifts driven by converging technological advances, regulatory evolution, and changing care delivery models. Devices that once served as rescue interventions are now being integrated earlier in clinical pathways as evidence accumulates about their impact on morbidity and survival, while miniaturization and remote-monitoring capabilities are reshaping outpatient management and follow-up intensity.

Simultaneously, precision medicine is moving from promise to practice. Gene therapies and targeted biologics are advancing through clinical development with increasingly sophisticated patient selection strategies that leverage genetic testing and biomarker profiling. This is accompanied by a rethinking of clinical trial designs toward adaptive models and real-world endpoints that better reflect heterogeneous patient populations. The pharmacological landscape remains important, with refined small molecules and novel biologic constructs aimed at neurohormonal modulation and myocardial remodeling complementing device-based modalities.

Distribution and care settings are being reimagined; hospitals remain centers of acute care and implantation, but a shift toward homecare, remote titration, and specialty clinics for longitudinal management is evident. These delivery changes are enabled by digital health platforms, interoperability between monitoring devices and electronic records, and greater emphasis on patient-reported outcomes. Collectively, these shifts are not incremental but structural, altering how products are developed, positioned, and reimbursed, and placing a premium on integrated strategies that bridge devices, biologics, and services.

Assessment of how 2025 tariff shifts are reshaping global manufacturing, procurement, and pricing strategies across devices, biologics, and gene therapy inputs in cardiomyopathy care

The introduction of new tariff measures in 2025 adds a significant layer of complexity to global supply chains and cost structures in dilated cardiomyopathy therapeutics, particularly for components and biologic inputs that cross international borders. Medical devices such as cardiac resynchronization therapy systems, implantable cardioverter-defibrillators, and ventricular assist devices depend on intricate global manufacturing networks for semiconductors, sensors, and specialized alloys. Tariff-induced cost pressures on upstream suppliers can cascade to device manufacturers, creating potential pricing tensions for hospitals and purchasers.

On the pharmacological and gene therapy side, manufacturing inputs for vectors, viral production, and complex biologic reagents often involve cross-border sourcing of raw materials and specialized processing equipment. Increased import duties or customs friction can lengthen lead times and raise production costs, prompting sponsors to re-evaluate contract manufacturing strategies, regionalize production, or accelerate technology transfers. These operational responses can mitigate exposure but require capital investment and regulatory coordination that take time to realize.

For health systems and payers, the net effect of tariff-driven cost changes may be felt through procurement cycles and capital budgeting for device programs, as well as through negotiated pricing for high-cost biologics and gene-based therapeutics. In response, manufacturers may pursue differentiated pricing models, local manufacturing partnerships, or outcomes-based contracting to preserve access while maintaining commercial viability. Finally, regulatory and reimbursement stakeholders are likely to scrutinize value propositions more closely, linking coverage decisions to robust clinical and economic evidence as part of a broader adaptation to changing input costs.

Integrated segmentation insights that connect therapeutic classes, treatment modalities, administration routes, care settings, and distribution channels to clinical and commercial strategy

A segmentation-aware view of dilated cardiomyopathy therapeutics reveals differentiated opportunities and adoption dynamics when consideration is given to therapeutic class, treatment modality, administration route, end-user environment, and distribution pathway. When therapeutic class is parsed into ACE inhibitor, Arb, Arni, Beta Blocker, Device Therapy, Diuretic, and Gene Therapy, it becomes clear that medical management remains foundational while device therapy and gene therapy introduce distinct clinical and commercial characteristics; further granularity in device therapy across Crt, Icds, and Vad highlights heterogeneous investment and care pathway requirements. Looking through the lens of treatment modality-Device Based, Gene Therapy, and Pharmacological-and recognizing that pharmacological development bifurcates into Biologics and Small Molecule approaches-clarifies where development risk and regulatory complexity converge versus where incremental clinical optimization is more feasible.

Route of administration further stratifies operational considerations: Intravenous modalities carry implications for inpatient or clinic-based delivery infrastructures, whereas Oral therapies enable broader outpatient management and adherence-focused interventions. End user segmentation across Homecare, Hospital, and Specialty Clinic settings emphasizes shifting touchpoints for follow-up, titration, and device monitoring, with homecare growth accelerating needs for remote monitoring and caregiver support. Finally, distribution channel differentiation among Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies shapes logistics, inventory strategies, and patient access patterns, influencing how manufacturers and payers design distribution agreements and patient support programs.

Integrating these segmentation dimensions enables a clearer mapping of clinical value to commercial levers. For example, gene therapy candidates may require specialized distribution and hospital-based administration while oral small molecules can be deployed broadly through retail pharmacies. Devices necessitate capital procurement and post-implant surveillance, elevating the importance of durable service agreements and interoperability with clinical IT systems. Understanding these intersections is critical for prioritizing R&D investments, tailoring market access plans, and designing patient-centered support models.

Regional dynamics analysis describing how heterogeneous regulatory, reimbursement, and infrastructure factors in the Americas, EMEA, and Asia-Pacific influence therapy adoption and access

Regional dynamics are shaping the development, adoption, and delivery of dilated cardiomyopathy therapeutics in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, mature care infrastructures and well-established reimbursement frameworks support rapid adoption of advanced devices and next-generation biologics, though payers increasingly demand rigorous health-economic evidence to justify high-cost interventions. Clinical networks and specialized centers of excellence facilitate complex procedures and clinical trial enrollment, while private and public payers negotiate coverage conditions that influence commercialization strategies.

Across Europe, Middle East & Africa, the region exhibits considerable heterogeneity driven by national regulatory, reimbursement, and health system structures. Western European markets often mirror North American pathways with structured adoption of devices and biologics, whereas emerging markets within the region face capacity constraints that may delay deployment of complex therapies. Policy emphasis on cost-effectiveness and centralized HTA processes shapes pricing strategies and can incentivize local evidence generation or managed entry agreements.

In the Asia-Pacific region, rapid investments in hospital infrastructure and a growing emphasis on cardiovascular disease management are expanding patient access to advanced therapies. Regulatory pathways in several jurisdictions have been modernized to facilitate expedited review for innovative therapeutics, and local manufacturing initiatives are increasingly pursued to reduce import dependency. Regional collaboration and harmonization efforts are creating new avenues for clinical research and could accelerate broader adoption of device-based and gene-focused interventions when combined with strategic partnerships and localized market access approaches.

Corporate positioning and competitive maneuvers revealing how device leaders, biologics developers, and gene therapy pioneers are aligning capabilities for long-term advantage

The corporate landscape in dilated cardiomyopathy therapeutics is marked by strategic convergence between large diversified device manufacturers, specialist biologics developers, and emerging gene therapy innovators. Established cardiovascular device firms continue to invest in next-generation implantable systems, remote monitoring ecosystems, and peri-procedural service models that enhance long-term patient outcomes and create recurring service revenues. These incumbents often pursue bolt-on acquisitions, co-development partnerships, and broad-based clinical programs to sustain device leadership while expanding into adjacent value-added services.

Biopharmaceutical companies with cardiovascular portfolios are diversifying through targeted biologics and small-molecule programs that address myocardial remodeling and neurohormonal pathways. Simultaneously, biotechnology firms focused on gene editing and vectorized gene replacement are advancing candidates that target defined genetic etiologies of dilated cardiomyopathy, fostering collaborations with manufacturing specialists and clinical research networks to manage development complexity and scale-up risks. Cross-sector alliances between device makers and biologic developers are becoming more common, particularly where combination therapies or diagnostic-enabled patient selection can enhance therapeutic impact.

Competitive differentiation increasingly hinges on evidentiary depth, post-market surveillance capabilities, and the ability to demonstrate real-world value. Companies that invest in longitudinal data platforms, patient support programs, and integrated care solutions are better positioned to engage payers and care providers. Moreover, strategic moves such as regional manufacturing investments, outcomes-based contracting pilots, and early engagement with regulatory agencies are shaping which players can effectively translate scientific advances into sustainable commercial success.

Actionable strategic imperatives for leaders to fortify evidence generation, supply resilience, and integrated commercialization across therapeutics and care settings

Industry leaders should pursue a multi-dimensional strategy that prioritizes evidence generation, supply chain resilience, and integrated commercialization to capture clinical and commercial value in dilated cardiomyopathy therapeutics. First, strengthening the evidence base through pragmatic trials, real-world evidence programs, and registries will be essential to convince clinicians and payers of incremental benefits, particularly for high-cost devices and gene-based therapies. Building interoperable data platforms that facilitate long-term outcome tracking will support value-based conversations and post-market commitments.

Second, diversifying manufacturing footprints and establishing qualified regional partners can mitigate tariff and logistics risks while reducing lead times for critical inputs. Investing in technology transfer and quality systems in strategically selected regions will enable faster response to demand shifts and regulatory requirements. Third, commercial strategies must be aligned to care settings: tailored access programs for hospital procurement, streamlined pathways for specialty clinics, and patient adherence solutions for oral therapies will improve uptake across end-user segments.

Finally, forging cross-sector partnerships-linking device capabilities with pharmacological innovations and digital health tools-can create differentiated offerings that address both clinical and operational pain points. Leaders should also engage early with regulators and HTA bodies to co-design evidence packages and explore innovative reimbursement arrangements. Executed together, these actions will help organizations navigate evolving policy environments, demonstrate sustainable value, and enhance patient access to advanced therapies.

Transparent methodology integrating literature synthesis, stakeholder interviews, clinical registry analysis, and scenario evaluations to support robust strategic conclusions

The research underpinning this executive analysis combined a structured review of peer-reviewed literature, regulatory filings, and clinical trial registries with targeted primary engagements across the ecosystem. Literature synthesis included recent guidelines, consensus statements, and high-impact clinical studies to ensure alignment with current standards of care. Clinical trial registries and public regulatory filings were examined to map investigational programs and expected milestones for device and gene therapy candidates.

Primary research consisted of interviews with cardiologists, electrophysiologists, health system procurement leads, clinical researchers, and patient advocacy representatives to capture front-line perspectives on adoption barriers and clinical unmet needs. These qualitative insights were triangulated with secondary sources, including manufacturing and supply chain publications, technology briefs, and policy analyses, to assemble a holistic view of operational and regulatory dynamics. Data quality protocols involved cross-validation of key assertions against multiple independent sources and sensitivity checks to identify areas of higher uncertainty.

Analytical approaches included segmentation mapping across therapeutic class, modality, administration route, end user, and distribution channel, as well as scenario-based assessment of tariff and supply chain impacts. The methodology emphasized transparency in assumptions and explicit documentation of evidence sources to facilitate verification and to support subsequent deep-dive investigations.

A conclusive synthesis highlighting how clinical innovation, evidence depth, and operational adaptability will determine future adoption and access in dilated cardiomyopathy care

Dilated cardiomyopathy therapeutics are at an inflection point where device innovation, biologic advancement, and genomic medicine are converging to expand treatment possibilities while simultaneously increasing complexity across development, delivery, and reimbursement pathways. Stakeholders who can integrate clinical rigor with operational agility will be best positioned to translate scientific progress into meaningful patient outcomes and sustainable commercial models. The evolving care landscape requires a recalibration of investment priorities, with emphasis on evidence generation, regional supply chain strategies, and value-aligned commercialization.

Adoption trajectories will be shaped not only by clinical efficacy but also by the ability to demonstrate real-world benefit, manage total cost of care, and adapt to shifting policy environments such as tariff-induced supply changes and evolving HTA expectations. Cross-disciplinary collaboration among clinicians, manufacturers, payers, and regulators will be essential to navigate these dynamics and to create durable pathways for patient access. Ultimately, the organizations that combine scientific excellence with pragmatic delivery models and strong stakeholder engagement will set the cadence for the next era of dilated cardiomyopathy care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dilated Cardiomyopathy Therapeutics Market, by Therapeutic Class

  • 8.1. ACE Inhibitor
  • 8.2. ARB
  • 8.3. ARNI
  • 8.4. Beta Blocker
  • 8.5. Device Therapy
    • 8.5.1. CRT
    • 8.5.2. ICDS
    • 8.5.3. VAD
  • 8.6. Diuretic
  • 8.7. Gene Therapy

9. Dilated Cardiomyopathy Therapeutics Market, by Treatment Modality

  • 9.1. Device Based
  • 9.2. Gene Therapy
  • 9.3. Pharmacological
    • 9.3.1. Biologics
    • 9.3.2. Small Molecule

10. Dilated Cardiomyopathy Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Dilated Cardiomyopathy Therapeutics Market, by End User

  • 11.1. Homecare
  • 11.2. Hospital
  • 11.3. Specialty Clinic

12. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Dilated Cardiomyopathy Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dilated Cardiomyopathy Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dilated Cardiomyopathy Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Dilated Cardiomyopathy Therapeutics Market

17. China Dilated Cardiomyopathy Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. Amicus Therapeutics
  • 18.8. Astellas Pharma Inc
  • 18.9. AstraZeneca plc
  • 18.10. Bayer AG
  • 18.11. Biogen Inc.
  • 18.12. BioMarin Pharmaceutical Inc
  • 18.13. C.H. Boehringer Sohn AG & Co. KG
  • 18.14. Daiichi Sankyo Company, Limited
  • 18.15. Eli Lilly and Company
  • 18.16. Gilead Sciences, Inc.
  • 18.17. GlaxoSmithKline (GSK)
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Kyowa Kirin Co, Ltd
  • 18.20. Merck & Co., Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Regeneron Pharmaceuticals, Inc.
  • 18.24. Roche Holding AG
  • 18.25. Sanofi S.A.
  • 18.26. Sarepta Therapeutics
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. The Bristol-Myers Squibb Company
  • 18.29. The Takeda Pharmaceutical Company Limited
  • 18.30. Vertex Pharmaceuticals
  • 18.31. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 157. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 181. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)